Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7,144 JPY | +0.21% | -4.61% | +5.09% |
May. 14 | Japan's Nikkei drifts sideways as more earnings, US CPI awaited | RE |
May. 13 | Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an enterprise value anticipated at 3.49 times the sales for the current fiscal year, the company turns out to be overvalued.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.09% | 13B | A- | ||
+34.35% | 693B | C+ | ||
+29.39% | 584B | B | ||
-3.49% | 372B | C+ | ||
+20.15% | 332B | B- | ||
+6.19% | 294B | C+ | ||
+14.11% | 239B | B+ | ||
-3.03% | 211B | A+ | ||
+10.02% | 210B | B- | ||
+9.21% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4507 Stock
- Ratings Shionogi & Co., Ltd.